Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Inhibikase Therapeutics, Inc. filed a current report noting that it has announced its financial results for the quarter ended June 30, 2025 and provided other corporate updates through a press release. The press release is furnished as an exhibit and is not treated as part of the company’s formal, liability-bearing SEC filings unless later specifically incorporated by reference.
The company also updated its corporate presentation for use in meetings with investors, analysts and others, and furnished this presentation as a separate exhibit. Both the press release and the presentation are being shared for informational purposes under the Exchange Act without being deemed formally filed.
This Schedule 13G is filed jointly by Sands Capital Life Sciences Pulse Fund II, L.P., Sands Capital Alternatives, LLC and Frank M. Sands and reports a significant passive position in Inhibikase Therapeutics common stock. The Reporting Persons beneficially own 10,950,000 shares, representing 14.7% of the outstanding class based on 74,341,540 shares outstanding as of May 1, 2025. The position is reported with shared voting and dispositive power of 10,950,000 shares and no sole voting or dispositive power.
The filing expressly excludes a Series A-1 warrant to purchase 5,475,000 shares and a Series B-1 warrant to purchase 10,068,120 shares because neither warrant is exercisable within 60 days; each warrant contains a restriction preventing beneficial ownership in excess of 19.99% immediately after exercise. The Reporting Persons certify the securities are not held to change or influence control of the issuer.
Form 4/A overview: Inhibikase Therapeutics (IKT) filed an amended Form 4 for President & Head of R&D Christopher Cabell. The filing corrects the exercise price to $2.97 on a previously reported stock-option grant covering 1,100,705 common shares originally awarded on Feb 21 2025 and expiring on Feb 21 2035. No other terms change: the options vest in three substantially equal tranches on the 2nd, 3rd and 4th anniversaries of the grant date, contingent on continued service. The amendment does not involve any share sales or purchases and therefore has no immediate cash impact on the company. It simply aligns the public record with the correct contractual terms, maintaining disclosure accuracy and avoiding potential misinterpretation of executive compensation.